RETRACTED: Dominant-negative effects of a novel mutation in the filamin myopathy (Retracted article. See vol. 75, pg. 2138, 2010)
NEUROLOGY
Authors: Kono, S.; Nishio, T.; Takahashi, Y.; Goto-Inoue, N.; Kinoshita, M.; Zaima, N.; Suzuki, H.; Fukutoku-Otsuji, A.; Setou, M.; Miyajima, H.
Abstract
Background: Filamin myopathy is associated with mutations in the filamin C gene ( FLNC) and is a myofibrillar myopathy characterized by focal myofibrillar destruction and cytoplasmic aggregates containing several Z-disk-related proteins. Methods: This study investigated 6 Japanese patients with dominantly inherited myofibrillar myopathy manifested by adult-onset, slow and progressive muscle weakness and atrophy in the distal extremities. Results: The abundantly expressed proteins in the affected muscles were identified as filamin C by nano liquid chromatography-tandem mass spectrometry. A genetic analysis of FLNC identified a heterozygous c.8107delG mutation that was localized to the dimerization domain of filamin C. A biochemical crosslinking analysis of bacterially expressed recombinant wild-type and mutant filamin C fragments demonstrated that the mutant monomer disturbed the proper dimerization of the wild-type filamin dimer, resulting in formation of a heterotrimer with the wild-type filamin dimer. The expression study in C2C12 myoblasts showed that the mutant filamin fragments formed cytoplasmic aggregates with endogenous wild-type filamin C. Conclusions: This study provides evidence for the dominant-negative effects of the FLNC mutation. These effects may be mutation-specific and likely result in the variation in the clinical phenotypes seen in patients with filamin myopathy. Neurology (R) 2010; 75: 547-554
Response by Ma et al to Letter Regarding Article, "Novel Mutation in FLNC (Filamin C) Causes Familial Restrictive Cardiomyopathy"
CIRCULATION-GENOMIC AND PRECISION MEDICINE
Authors: Tucker, Nathan R.; Ellinor, Patrick T.
Abstract